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22 Oral Presentationsthan 18 years of age. All patients had acute leukemia and were trans-
planted in 2000–2006. Median follow-up of surviving patients was 2
years in both treatment groups. There were no significant differences
in patient and disease characteristics, transplant conditioning
regimen, GVHD prophylaxis and donor-recipient HLA disparity
by graft type. Though the early probability of neutrophil recovery
($500/ul) was faster after transplantation of PBPC (31% vs. 10%
at day-14, p\0.001) the probability of recovery by day-28 was similar
after PBPC and BM transplants (94% and 91%, p5 0.391). Platelet
recovery ($20,000/ul) was better after PBPC transplants (86% vs.
76% at day-60, p 5 0.022). Risks of grade 2–4 (hazard ratio [HR]
1.24, p 5 0.147) and grade 3–4 (HR 1.07, p 5 0.785) acute
GVHD were similar after PBPC and BM transplants. The risk of de-
veloping chronic GVHD was significantly greater after PBPC trans-
plants compared to BM transplants (HR 2.36, p\0.001). After
adjusting for disease status, donor-recipient HLA disparity and
age, TRM, relapse, leukemia-free survival and overall survival were
similar after PBPC and BM transplants. In parentheses is shown
the day-100 probability of grade 2–4 acute GVHD (53%/49%) the
3-year probabilities of chronic GVHD (58%/33%), TRM (20%/
24%), relapse (34%/28%), LFS (46%/48%) and overall survival
(49%/49%) for the PBPC/BM groups, respectively. These results
differ from transplantation of PBPC from HLA-matched siblings
To conclude, in patients \18 years of age with acute leukemia,
unrelated PBPC transplant compared to BM resulted in faster recov-
ery of neutrophils and platelets and an increased risk of chronic
GVHD. Acute GVHD, TRM, relapse, survival and LFS were
similar using PBPC or BM.LYMPHOMA/MULTIPLE MYELOMA
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COMPLETE TUMOR RESPONSES IN LYMPHOMA PATIENTSWHO RECEIVE
AUTOLOGOUS CYTOTOXIC T LYMPHOCYTES TARGETING EBV LATENT
MEMBRANE PROTEINS
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EBV-associated Hodgkin’s Lymphoma (HL) and some non-
Hodgkins lymphoma (NHL) have type II viral latency expressing
the subdominant EBV antigens EBNA1, LMP1 and LMP2. These
antigens may serve as targets for immunotherapy approaches after
stem cell transplant. We hypothesized that CTL enriched for effec-
tor cells specifically targeting LMP antigens would have efficacy in
HL and NHL patients. LMP-CTL were generated using dendritic
cells for initial stimulations then EBV-transformed lymphoblastoid
cell lines (LCL) both of which had been genetically modified to over-
express either LMP2 alone or inactive LMP1 (DLMP1) and LMP2
by transduction with an Ad5f35LMP2 (n 5 16) or Ad5f35DLMP1-
I-LMP2 (n5 14) vector respectively. All LMP-CTL lines were poly-
clonal comprising CD41 (mean 17618%; range 1–92) and CD81
(mean 74 6 25%; range 1–99) T-cells. Flow cytometric analysis of
memory markers revealed mixed populations of CD45RA-
CD62L- T-cells (45615%; range 31–63) and CD45RA- CD62L1
T-cells (3465%; range 28–41). The CTL lines had specificity for
CD41 and CD81 restricted LMP2 epitopes alone (n 5 19; mean
1; range 0–7) or both LMP1 and LMP2 epitopes (n 5 13; mean 2;
range 0–6) per CTL line, as determined using overlapping LMP1
and LMP2 peptide pools in ELISPOT assays. 24 patients with
EBV1 HL and NHL have been treated on dose escalation studies.
16 with LMP2 CTLs and 8 with LMP1/2 CTLs. No immediate
toxicity was observed. After CTL infusion, increased numbers of
LMP-specific T cells were detected in the blood of 15/22 evaluable
patients, (range 2 to 70 fold) persisting for up to 3 months. Addition-
ally, two patients had lymph node biopsies 3–6 months post CTL,
which showed selective accumulation of LMP2-multimer positive
cells in lymph nodes. 12/13 high-risk and/or multiply relapsed pa-
tients who received LMP-CTL as adjuvant treatment after SCT or
chemotherapy remained in remission for a median of 2yrs (range
. 3mths to 5years) after CTL. 11 patients had detectable disease
at the time of CTL, 2 of these had progressive disease by 8 wks
and 9 had clinical responses. The median duration of the clinical
responses is 1 yr with one stable disease (.12months), one partialresponse (36 months), and 7 complete responses (range 9 months
to .4.5 years). In conclusion, immunotherapy with CTL targeting
LMP antigens is well tolerated in patients with EBV1 lymphoma
and infused LMP-CTL can accumulate at tumor sites and induce
complete and sustained clinical responses.53
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Patients with advanced stage Mycosis Fungoides (MF), Sezary syn-
drome (SS) and other less common subtypes of primary CTCL have
a dismal prognosis with conventional therapy. A potential role for
alloSCT in these patients has been suggested by a small number of
case-reports and small series. We have now conducted a retrospective
registry analysis of 64 recipients of an alloSCT from HLA-Identical
donors (52 related, 12 unrelated) for advanced CTCL reported to
EBMT between 1997 and 2006: 23 MF, 21 SS, 16 primary cutaneous
anaplastic large cell lymphoma and 4 subcutaneous panniculitis-like
T-cell lymphoma; 38 male/26 female; median age 46 (5–65); median
follow up in survivors, 28 months). AlloSCT was performed at a me-
dian of 22 (3–313) months from initial diagnosis, following a median
of 3 (1–8) prior lines of therapy, 54 PB and 10 BM as stem cell source,
and using a reduced-intensity conditioning (RIC) in 41 (64%) cases.
Only 23% of patients were in CR and 26% in PR at the time of al-
loSCT. The rest were primary refractory (RE, 25%) or in progression
(PG, 26%). Non-relapse mortality was 24% at 3 years, and appeared
poorer in patients receiving myeloablative conditioning (MAC) than
in those receiving RIC alloSCT (35% vs 16%; p5 0.06). Acute graft
versus host disease (GVHD) occurred in 37% of patients at risk, and
chronic GVHD in 69% of patients alive at day1100. The cumulative
incidence of disease relapse (36% at 3 years) was significantly higher
in patients with advanced disease status at alloSCT (RE/PG 46% vs
CR/PR 21%; p 5 0.01), but similar between related and unrelated
donors (p5 0.39) and between MAC and RIC (p5 0.58). First pro-
gression free survival (PFS) at 3 years was 41%, with a significant ad-
vantage for patients in CR/PR at alloSCT (58% vs 26%; p\0.01), but
not for type of conditioning (MAC 45% vs RIC 44%; p 5 0.44) or
donor type (related 46% vs unrelated 33%; p5 0.17). Out of 22 pa-
tients who relapsed, 10 remain alive and 4 of these are in CR at last
follow up, indicating that a proportion of patients can achieve a better
control of their CTCL following relapse after alloSCT. Overall sur-
vival for the whole series was 55% at 3 years, with a trend towards an
improved OS for patients with disease in CR/PR at transplant (65%
vs 46%; p 5 0.12). Overall, this outcome appears superior to the
expected median OS for these patients with conventional therapy,
and reinforces, in the largest series to date, the important role of
alloSCT in advanced stage CTCL.54
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Autologous hematopoietic cell transplantation (auto HCT) is ef-
fective therapy for patients with advanced Hodgkin (HL) and non-
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HCT for HL and NHL have not been well described. We conducted
a retrospective cohort study to evaluate the probability and risk fac-
tors for long-term survival and late relapse in this population. Recip-
ients of auto HCT for HL (N5 407) and NHL (N5 960) between
1990 and 1998 reported to the CIBMTR and in continuous complete
remission (CR) for at least 2 years post-HCT were included in this
study . The median followup was 104 (range, 25–203) months for
HL and 107 (range, 25–198) months for NHL. NHL subtypes
were follicular (30%), diffuse large cell (45%), mantle cell (6%) and
other (7%). The median age of HL patients was 31 years compared
to 47 years for NHL; more HL patients were\20 years (15% vs
5%) while NHL patients were .50 years (6% vs 40%). Patients
were predominantly White (87%), male (60%), with chemosensitive
disease (82%),and KPS score$90 (67%). A greater proportion of HL
patients had history of B symptoms (52% vs 34%) and were $12
months from diagnosis (90% vs 59%) while use of total body irradi-
ation (TBI) was more prevalent for NHL (94% vs 64%). The prob-
ability of overall survival (OS) and cumulative incidence of relapse
and non-relapse mortality (NRM) at 10-years after HCT was 76%
(95% CI, 73–79%), 17% (13–22) and 13% (9–17%) for HL. The
10-year rates of OS, relapse and NRM for NHL were 77%
(72–82%), 26% (23–30%) and 11% (9–13%). On multivariate anal-
ysis, OS (Table) was significantly associated with histology, age at
HCT and time from diagnosis to HCT. Factors predictive for relapse
included histology (compared to HL, relative risk (RR) 1.5 (1.0–2.2)
for follicular, 1.4 (0.9–1.9) for diffuse large cell, 1.4 (0.8–2.8) for lym-
phoblastic/Burkitts, 4.6 (2.8–7.6) for mantle cell and 1.5 (0.9–2.4) for
other NHL), male gender (RR 1.3 (1.0–1.6)), use of TBI (RR 1.6 (1.2–
2.1)), use of growth factors (RR 1.5 (1.1–2.0)) and time since diagnosis
of $12 months (RR 1.9 (1.5–2.6)) while KPS score of $90 at HCT
decreased relapse risk (RR 0.8 (0.6–1.0)). Recipients of auto HCT
for HL and NHL who remain in remission for at least 2 years have
a very favorable subsequent long-term survival. However, they
remain at risk for late relapse and NRM. Mantle cell histology, older
age at HCT and increasing time between diagnosis and HCT are
predictive of adverse long-term survival.
Multivariate analysis for overall survival in patients surviving in
remission for at least 2 years after auto HCT
Variable N RR of death (95%CI) P-valueHistology
HL 399 1.00 \0.01
Follicular NHL 282 0.91 (0.63-1.32) 0.61
Diffuse large cell NHL 422 0.92 (0.64-1.31) 0.63
Lymphoblastic/Burkitts NHL 69 1.28 (0.66-2.48) 0.47
Mantle cell NHL 57 2.87 (1.70-4.87) \0.01
Other NHL 117 0.95 (0.58-1.57) 0.85
Age at HCT
\20 years 101 1.00 \0.01
20-49 years 843 0.94 (0.54-1.66) 0.84
$50 years 402 2.23 (1.24-4.00) \0.01
Time from diagnosis to HCT
\12 months 426 1.00
$12 months 920 2.23 (1.62-3.09) \0.01Other variables considered: gender, race, KPS score, CR status, stage, B
symptoms, chemosensitivity, pre-HCT radiation, pre-HCT chemother-
apy regimens, HCT year, TBI use, graft source, graft purging, growth
factor use and post-HCTradiation.55
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Adoptive transfer of tumor-specific cytotoxic T lymphocytes
(CTLs) can induces tumor regression in patients with several types
of lymphomas. Clinical responses appear to require the in vivo expan-sion and persistence of the infused CTLs so that IL-2 has frequently
been used to support CTL therapies. Although effective, IL-2 is
associated with significant toxicity and the expansion of regulatory
T cells (Treg). Thus alternative cytokines able to sustain the expan-
sion of CTLs but avoiding the toxic and negative effects of IL-2 are
highly demanded. IL-7 plays a crucial role in T-cell homeostasis, ap-
pears well tolerated, and does not influence Treg numbers or func-
tion. Unfortunately, IL-7 may fail to expand tumor-specific CTLs
in vivo because these cells lack IL-7Ra expression. To determine
whether forced expression of transgenic IL-7Ra improves CTL sur-
vival and expansion we used Epstein-Barr-Virus specific-CTLs
(EBV-CTLs) which we transduced with a retroviral vector encoding
IL-7Ra. After transduction, IL-7Ra was detectable on 58–76% of
EBV-CTLs. The transgenic IL-7Ra molecule was functional since
addition of IL-7 induced STAT5 phosphorylation only in EBV-
CTLs/IL-7Ra1. These EBV-CTLs/IL-7Ra1 and control CTLs
expanded equally in response to IL-2, but only EBV-CTL/IL-
7Ra1 significantly proliferated in the presence of IL-7 (5 ng/mL)
[from 1  106 to 1.03  108 cells/ml (range, 0.38–2.9  108)] over
five weeks of culture. As anticipated, the EBV-CTL/IL-7Ra1 subset
of cells were selected on exposure to IL-7 and so formed an increasing
proportion of the total T cell population. Importantly, IL-7 expanded
EBV-CTLs/IL7Ra1 retained their ability to respond to other com-
mon-g-chain cytokines such as IL-2 and IL-15, and did not modify
their antigen specificity measured by tetramer staining and by
IFNg release. These CTLs also remained polyclonal, retaining
both their effector-memory profile and MHC-restricted killing of au-
tologous LCLs. Antigen or cytokine withdrawal abrogated CTL ex-
pansion. These in vitro characteristics were replicated in a xenograft
mouse model, in which EBV-CTLs/IL7Ra1 expanded in response
to IL-2 or IL-7 and maintained their antitumor effects. In conclusion,
we have developed a novel approach to safely expand adoptively trans-
ferred CTLs using IL-7. This approach can be beneficial for CTL
therapies in patients with lymphomas and other malignancies.PEDIATRIC DISORDERS
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SCD can be cured by HLA matched family donor AlloSCT (Wal-
ters et al, NEJM, 1996). Patients undergoing myeloablative Al-
loSCT are at risk for many complications post SCT including
death, graft versus host disease (GVHD), and life threatening infec-
tions, thus making RIC regimens an attractive alternative. Having an
unaffected, HLA-matched identical sibling is another major obstacle
for most SCD patients to proceed to AlloSCT(Bhatia et al, BMT,
2008). Umbilical cord blood (UCB) has been proven to be an excel-
lent alternate donor source that can safely reconstitute hematopoie-
sis after AlloSCT(Cairo et al, BBMT, 2008). In this study, we report
the results of RIC and AlloSCT from matched family and UCB do-
nors in 14 patients (12M:2F) with symptomatic SCD (HbSS 5 8,
HbSC 5 3, HbSßThal 5 3). Conditioning was Bu (4mg/kg  4d
# 4 yrs and 12.8mg/ kg  4d . 4 yrs), Flu (30mg/m2  6d), and
Alemtuzumab (2mg/m2  1d, 6mg/m2  2d, and 20mg/m2  2d).
Median age was 6.15 yrs (1.5–16). Donor sources: 6-6/6 HLA-
matched sibling bone marrow (BM), 2-6/6 sibling UCB, 3-4/6
and 3-5/6 unrelated UCB. Bone marrow recipients received median
cell doses of 5.463.5  108 TNC/kg and 4.9861.8  106 CD34/kg
while cord blood recipients received median cell doses of 4.162.0 
107 TNC/kg and 2.261.8  105 CD34/kg. All received tacrolimus
and mycophenolate mofetil as GVHD prophylaxis and phenytoin
or keppra as seizure prophylaxis for 180 days post SCT. Median neu-
trophil and platelet recovery was day 27(0–47) and day 43(0–86), re-
spectively. One patient had primary graft failure at day 160 post
